Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Prime Medicine (Nasdaq: PRME) closed its underwritten public offering, raising approximately $143.7 million in gross proceeds from common stock sales.

The offering comprised 41,071,428 shares at $3.50 per share, including the full exercise of the underwriters’ option to purchase 5,357,142 additional shares. All shares were sold by Prime Medicine. Gross proceeds are before underwriting discounts, commissions and offering expenses. Jefferies, TD Cowen and Goldman Sachs acted as joint book-running managers.

1 point · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

How the balance works

Positive

• Major pointApproximately $143.7 million in gross proceeds raised through the completed common stock offering. 18% of market cap

Negative

• Major point41,071,428 common shares issued at $3.50 per share dilute existing holders, including 5,357,142 option shares.
• Minor pointUnderwriting discounts, commissions and offering expenses reduce proceeds available to Prime Medicine.

News Explained

The issuance dilutes existing ownership; gross proceeds equal 360.4 days of third-quarter outflow, versus 153.4 days represented by September 30, 2026 cash and short-term investments.

The Prime Medicine offering has closed: the company sold common shares, increasing the share count and reducing existing holders’ percentage ownership absent offsetting changes.

The $143.7 million gross proceeds, before offering costs, equal 360.4 days of operating cash outflow at the third-quarter rate; cash and short-term investments at September 30, 2026 represented 153.4 days on the same basis.

Sources and calculations

• Prime Medicine offering closing release (2026-11-12)
• Dilution definition (version supplied)
• Prime Medicine third-quarter 2026 fundamentals (2026Q3)

• Offering gross against the last reported quarterly operating outflow, in days at that rate $143,700,000 / ($36,683,000 / 92) = 360.4 days
• Available liquidity against the last reported quarterly operating outflow, in days at that rate ($54,886,000 + $6,271,000) / ($36,683,000 / 92) = 153.4 days

Key Figures

Shares offered: 41,071,428 shares Additional shares: 5,357,142 shares Offering price: $3.50 per share +1 more

Shares offered

41,071,428 shares

Completed underwritten public offering

Additional shares

5,357,142 shares

Full exercise of the underwriters’ option

Offering price

$3.50 per share

Public offering

Gross proceeds

Approximately $143.7 million

Before underwriting discounts, commissions and offering expenses

Previous Offering Reports

1 past event · Latest: Aug 01

Same Type 1 event

1. Aug 01

   public offering

   24h Move

   +11.4%

   Prior completed offering sold 43.7 million shares at $3.30, generating approximately $144.2 million gross.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten public offering, shelf registration statement, form s-3asr, prospectus supplement

4 terms

underwritten public offering financial

"closing of its underwritten public offering of 41,071,428 shares"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3ASR"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3asr regulatory

"shelf registration statement on Form S-3ASR"

Form S-3ASR is a type of SEC registration that lets large, well-known public companies pre-register securities so they can be sold quickly when needed, similar to having a pre-approved credit line they can draw on at short notice. For investors, it matters because it signals a company's readiness to raise cash fast, which can affect share supply and price (dilution) and reveal how easily the company can fund growth or handle short-term needs.

prospectus supplement regulatory

"A final prospectus supplement relating to and describing the terms"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 41,071,428 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,357,142 additional shares of its common stock, at a public offering price of $3.50 per share. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $143.7 million.

Jefferies, TD Cowen and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. Oppenheimer & Co. and LifeSci Capital acted as passive book-running managers for the offering.

The shares of common stock were offered by Prime Medicine pursuant to a shelf registration statement on Form S-3ASR (File No. 333-291348) filed with the U.S. Securities and Exchange Commission (SEC) on November 7, 2025, as amended by that certain Post-Effective Amendment No. 1 to Form S-3 (No. 333-291348) and that certain Post-Effective Amendment No. 2 to Form S-3 (No. 333-291348), each filed with the SEC on March 3, 2026, and declared effective by the SEC on March 4, 2026. The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov.

Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Prime Medicine

Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around its core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high-value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path.

© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com

Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How much did Prime Medicine raise in its public offering and at what price?

Prime Medicine raised approximately $143.7 million in gross proceeds by selling 41,071,428 common shares at $3.50 per share. Proceeds are before underwriting discounts, commissions and offering expenses.

Did the underwriters fully exercise their option in Prime Medicine’s offering?

The underwriters fully exercised their option to purchase 5,357,142 additional common shares. Those shares are included in the offering’s total of 41,071,428 shares.